"rationale","description","label","uuid:ID","name","instanceType","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","","3b9280df-7965-46b9-987a-91177daf4bea","Study Design 1","StudyDesign","StudyDesign_1"
